VistaGen raises $3.75M for stem-cell derived drugs
South San Francisco, Calif.-based VistaGen Therapeutics, a biotech that uses human embryonic stem cells to discover new drugs, raised $3.75 million in a bridge financing as it prepares to raise up to $20 million in a fourth round. See our story in today’s briefing at VentureBeat Life Sciences.
Next Story: Biotech’s double standard on biogenerics
Previous Story: Life sciences briefing: Friday, Aug. 10, 2007
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.